Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
What dosimetric and technical precautions/guidelines do you follow when treating a patient with LVAD?
If target is within 5-6 cms of LVAD, what precautions do you take?
Related Questions
What are your top takeaways in Thoracic Cancers from ASTRO 2024?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
In ES-SCLC presenting with extensive brain metastases, how do you time whole brain radiation after the first cycle of chemotherapy has already been delivered?
How do you assess whether a patient will be a good DIBH candidate for lung or abdomen treatments?
For stage III-IV Hodgkin's lymphoma, would you consider consolidative radiation for bulky disease after a complete response was seen using N-AVD per the S1826 trial?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
In a patient with esophageal cancer with lymph node involvement, would you consider treating with definitive chemo-radiation if they have a single area of retroperitoneal metastasis?
Is it reasonable to extrapolate the findings of RT Charm and Alliance to intact breast patients and offer hypofractionated RNI to all patients who are eligible for RNI?